1 January 2018
EMA/798079/2017
EMEA/H/C/001166

Public statement

Clopidogrel Acino

Withdrawal of the marketing authorisation in the European Union

On 18 January 2017, the European Commission withdrew the marketing authorisation for Clopidogrel Acino (clopidogrel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Acino AG, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Clopidogrel Acino was granted marketing authorisation in the EU on 28 July 2009 for prevention of atherothrombotic events. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014.

Clopidogrel Acino is a generic medicine of Plavix. There are other generic medicinal products of Plavix authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Clopidogrel Acino will be updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact